IDO and TDO Inhibitors - Novel Immune Response Checkpoint Modulators; Competitor Analysis Report
The Competitive Intelligence report aboutIDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators provides a competitor analysis as of March 2015 in the development pipeline of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3- dioxygenase (TDO) for treatment of cancer as monotherapy and in combination with other immune checkpoint inhibitors. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database...
View full press release